EMA Authorised: Luxturna (voretigene neparvovec) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Luxturna (voretigene neparvovec) from Novartis Europharm Limited for the treatment of inherited retinal diseases Leber …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis
• Retinitis Pigmentosa

Drugs mentioned

• Luxturna (voretigene neparvovec-rzyl)

Snippet

Status: Authorised. Therapeutic area: Leber Congenital Amaurosis;Retinitis Pigmentosa. MAH: Novartis Europharm Limited. Decision date: 13/02/2026. Orphan medicine